Biomarin Pharmaceutical (BMRN) Enterprise Value: 2009-2025
Historic Enterprise Value for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $8.9 billion.
- Biomarin Pharmaceutical's Enterprise Value fell 28.35% to $8.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 billion, marking a year-over-year decrease of 44.22%. This contributed to the annual value of $11.4 billion for FY2024, which is 33.35% down from last year.
- Per Biomarin Pharmaceutical's latest filing, its Enterprise Value stood at $8.9 billion for Q3 2025, which was down 2.06% from $9.1 billion recorded in Q2 2025.
- Biomarin Pharmaceutical's Enterprise Value's 5-year high stood at $17.9 billion during Q4 2022, with a 5-year trough of $8.9 billion in Q3 2025.
- In the last 3 years, Biomarin Pharmaceutical's Enterprise Value had a median value of $14.4 billion in 2024 and averaged $13.5 billion.
- Per our database at Business Quant, Biomarin Pharmaceutical's Enterprise Value rose by 29.34% in 2023 and then tumbled by 36.77% in 2025.
- Biomarin Pharmaceutical's Enterprise Value (Quarterly) stood at $15.2 billion in 2021, then climbed by 17.99% to $17.9 billion in 2022, then decreased by 4.76% to $17.1 billion in 2023, then plummeted by 33.35% to $11.4 billion in 2024, then declined by 28.35% to $8.9 billion in 2025.
- Its Enterprise Value stands at $8.9 billion for Q3 2025, versus $9.1 billion for Q2 2025 and $12.2 billion for Q1 2025.